25^th World Congress on Pediatric Oncology and Cancer Care September 19-20, 2024 Paris, France

 

•      Physicians,
•      Early career scientists,
•      Medical schools
•      Pediatric cancer societies
•      Medical device  companies,
•      Medical professionals
•      Medical directors,
•      Oncologists,
•      Medical and pharmaceutical professionals
•      Academic researchers. 
•      Postdoctoral researcher.
•      Students, researchers, managers and business representatives. 

• All programs entry
• Reception banquet
• 2 Coffee breaks and snacks during the two days
• Handbook
• Lunch during the conference
• Conference souvenir
• Abstracts will be published in our referred journal
• 25% Discount on the manuscript publication fee
• Certification by the organizing committee
• Wi-Fi facility
• CME-CPD Credits
• 50% Discount for group of 10 members
• Localities Participation Benefits:
• 20% Discount will be provided for the participants, who are attending from the local universities and hospitals.

Market Analysis of Pediatric Oncology and Cancer Care (2016-2024)

Over the past eight years, the pediatric oncology and cancer care market has undergone significant transformation and expansion, driven by technological advancements, increased funding, heightened awareness, and innovative research. This period has been marked by notable improvements in treatment modalities, a deeper understanding of pediatric cancers, and a concerted effort to enhance the quality of life and survival rates for young patients.

Technological and Treatment Advancements

One of the most significant advancements in pediatric oncology has been the development and application of immunotherapy treatments. Immunotherapies, particularly CAR-T cell therapy, have revolutionized the treatment landscape for certain types of leukemia and lymphoma. CAR-T cell therapy, which involves modifying a patient's T-cells to attack cancer cells, has shown remarkable efficacy, even in cases where traditional treatments have failed. Additionally, advancements in precision medicine have allowed for treatments to be tailored based on the genetic makeup of individual tumors, leading to more effective and less toxic treatment protocols. Precision medicine involves comprehensive genomic profiling of tumors, enabling oncologists to identify specific mutations and select targeted therapies that are more likely to be effective.

Minimally invasive surgical techniques have also improved outcomes for pediatric cancer patients. These techniques reduce recovery times and minimize surgical trauma, which is particularly beneficial for young patients. Innovations such as laparoscopic and robotic-assisted surgeries have become more prevalent, allowing for precise removal of tumors with reduced postoperative complications.

Research and Funding

Increased research funding has been a critical driver of advancements in pediatric oncology. Government initiatives, non-profit organizations, and pharmaceutical companies have all played significant roles in this regard. The National Institutes of Health (NIH) and other governmental bodies have provided substantial grants for pediatric cancer research. Non-profit organizations, such as the St. Baldrick's Foundation, have also been pivotal in raising funds and supporting research initiatives.

Market Segmentation and Regional Analysis

The pediatric oncology market can be segmented by cancer type, treatment type, and end-user. By cancer type, the market includes leukemia, brain and central nervous system tumors, neuroblastoma, Wilms tumor, lymphoma, rhabdomyosarcoma, and others. Leukemia remains the most common type of cancer in children, with significant advancements in its treatment contributing to improved survival rates. Brain and central nervous system tumors are the second most common type, with ongoing research into targeted therapies showing promise. Neuroblastoma, a cancer that originates in immature nerve cells, has seen improved outcomes due to advances in immunotherapy and precision medicine.

By treatment type, the market includes chemotherapy, radiation therapy, surgery, stem cell transplantation, targeted therapy, and immunotherapy. Chemotherapy, despite its side effects, remains a cornerstone of pediatric cancer treatment. Radiation therapy has seen improvements in precision, reducing damage to healthy tissues. Surgery, particularly minimally invasive techniques, plays a crucial role in the management of solid tumors. Stem cell transplantation is used for certain types of cancers and has seen advancements that improve success rates. Targeted therapy and immunotherapy are rapidly growing segments, driven by continuous research and development.

Challenges and Future Outlook

Despite the advancements, the pediatric oncology market faces several challenges. High treatment costs remain a significant barrier, particularly in low- and middle-income countries. The cost of advanced treatments like CAR-T cell therapy can be prohibitive, limiting access for many patients. Additionally, geographic and economic disparities can restrict access to the latest treatments and clinical trials, underscoring the need for more equitable healthcare solutions.

The psychosocial impact of pediatric cancer on patients and their families is another significant challenge. Comprehensive support services, including psychological counseling and social support, are essential to address the emotional and psychological needs of young patients and their families.

Final Paper Submission Deadline: 01 September, 2024

Early Bird Registration Deadline: 28 July, 2024
Notification of Abstract Acceptance/ Rejection: 1-2 days.

Conference Dates: 19-20 September, 2024

Group registration (Minimum 5 members) can avail 20% waivers from the registration fee.

Email: Program Manager at [email protected] or WhatsApp at (+44) - 7915641825 with details of the 5 participants

Abstract submission guidelines for Paediatrics Cancer Congress 2024 conferences:

• If you choose to participate in this conference, you need to submit an abstract
• The abstract should carry the summary of a research
• Abstract should be submitted either through e-mail or using the link given below
• Abstracts should be based on any areas as listed in this website as sessions/tracks

The overarching goal of Pediatric Cancer Congress 2023 is to confer honorary awards to deserving young researchers, scientists, young investigators, post-graduate students, post-doctoral fellows, trainees, and junior professors, acknowledging their outstanding contributions to the conference theme. The Young Scientist Awards aim to provide early-career academicians with a robust professional development opportunity, fostering the exchange of expertise on all facets of cancer care and oncology Read More....